Polymyxin B sulfate and trimethoprim (PBT) are two antibiotics used to treat a wide range of bacterial infections. PBT has been in use for more than 40 years, and is now the most commonly prescribed antibiotic combination in the United States. PBT is effective against most Gram-positive and Gram-negative bacteria, and has been used to treat a variety of infections, including urinary tract infections, skin and soft tissue infections, and respiratory tract infections. In this comprehensive guide, we will discuss the indications, pharmacology, and clinical use of PBT, as well as potential adverse effects and drug interactions.
PBT is indicated for the treatment of a wide range of bacterial infections, including urinary tract infections, skin and soft tissue infections, and respiratory tract infections. It is also approved for the treatment of certain sexually transmitted diseases, including gonorrhea and chlamydia. PBT is also used off-label to treat a variety of other infections, including meningitis, endocarditis, and sepsis.
PBT is a combination of two antibiotics, polymyxin B sulfate and trimethoprim. Polymyxin B is a polypeptide antibiotic derived from the bacterium Bacillus polymyxa. It works by binding to the outer membrane of Gram-negative bacteria, causing disruption of the cell membrane and leakage of intracellular components. Trimethoprim is a synthetic antibiotic that inhibits the synthesis of dihydrofolate reductase, an enzyme involved in the synthesis of folate, a cofactor for the synthesis of nucleic acids. By inhibiting the synthesis of folate, trimethoprim interferes with the synthesis of nucleic acids, preventing bacterial replication.
PBT is generally well tolerated and is effective against most Gram-positive and Gram-negative bacteria, including many resistant strains. It is usually administered orally, although it can also be administered intravenously. The usual dose is one tablet (500mg polymyxin B sulfate and 200mg trimethoprim) taken twice daily for seven to ten days. The dose may need to be adjusted for patients with renal impairment.
As with any medication, PBT can cause adverse effects. The most common side effects include nausea, vomiting, diarrhea, and rash. Other more serious side effects, such as anaphylaxis and Stevens-Johnson syndrome, have been reported in rare cases. PBT can also interact with other medications, including antacids, diuretics, and warfarin. It is important to tell your doctor about all medications you are taking before starting PBT.
Polymyxin B sulfate and trimethoprim (PBT) is a combination antibiotic used to treat a wide range of bacterial infections. It is generally well tolerated and is effective against most Gram-positive and Gram-negative bacteria, including many resistant strains. While PBT is generally safe and effective, it can cause adverse effects and interact with other medications, so it is important to tell your doctor about all medications you are taking before starting PBT. With proper use, PBT can be a powerful tool in the fight against bacterial infections.
1.
NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.
2.
In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.
3.
FDA Expands Durvalumab Label to Operable Lung Cancer
4.
New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations
5.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
1.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
2.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
3.
Unveiling the Hidden Benefits of Lymphedema Treatment
4.
IGF2BP1 in Blood Disorders: Therapeutic Potential and Comprehensive Functional Insights
5.
Florinef: Understanding Its Uses and Side Effects
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
3.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation